Boehringer’s Hernexeos was one of the 18 drugs selected so far for the FDA Commissioner’s National Priority Voucher Program that allows speedy process and cuts the review time to one to two months from the typical 10 to 12 months
Source:
www.thehindu.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
